{"title":"声门下狭窄的办公室类固醇注射。","authors":"Ramon A. Franco Jr MD","doi":"10.1016/j.otot.2023.05.009","DOIUrl":null,"url":null,"abstract":"<div><p><span><span><span>Serial Intralesional Steroid Injection (SILSI) has been gaining popularity among patients and physicians as a first-line treatment<span> for idiopathic subglottic stenosis. Patients are followed by in-office and at-home </span></span>spirometry to assess the </span>peak inspiratory flow<span><span> (PIF), peak expiratory flow (PEF) and the PEF% values, along with quality-of-life instruments such as the RAND36, EQ5D and the new subglottic stenosis-specific, iSGS6. The initial procedure can be performed in the operating room using balloons and cold instruments to remove the subglottic scarring with injection of </span>triamcinolone acetate 40 mg/cc into the subglottis. Subsequent injections are performed in the awake-office setting at 3-week intervals until reaching a total of 6 injections (1 at surgery + 5 in-office). This single-surgeon experience with SILSI at Mass Eye and Ear now spans 13+ years, 95 patients and over 1,000 injections. A total of 58% (55/95) of patients have only required one SILSI Round (4 to 6 injections) while we have an overall success rate of 96% (91/95). A total of 95% of subjects (90/95) tolerated awake SILSI. The 52 patients with greater than 2 years of follow-up have an average follow-up of 68 months. As a group they started at a PEF% of 55% and ended their SILSI at a PEF% of 93%. Their most recent PEF% is 92% reflecting the lasting efficacy SILSI offers. As a group they underwent an average of 7 steroid injections and 1.6 surgeries resulting in an average of 36 months between interventions. A total of 29% of patients (15/52) in the Long-Term group have not had recurrences in the 53 months they have been followed. They have a group PEF% of 94% highlighting the durable SILSI effects allowing them to breath without restriction. SILSI is a safe and reliable method to treat airway stenosis that is rooted in many years of clinical success. These patients have excellent </span></span>quality of life<span> and can maintain a high level of breathing for much longer than those treated with balloon dilation (36 months vs. 12 months).</span></p></div>","PeriodicalId":39814,"journal":{"name":"Operative Techniques in Otolaryngology - Head and Neck Surgery","volume":"34 2","pages":"Pages 120-128"},"PeriodicalIF":0.0000,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":"{\"title\":\"Office based steroid injections for subglottic stenosis\",\"authors\":\"Ramon A. Franco Jr MD\",\"doi\":\"10.1016/j.otot.2023.05.009\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p><span><span><span>Serial Intralesional Steroid Injection (SILSI) has been gaining popularity among patients and physicians as a first-line treatment<span> for idiopathic subglottic stenosis. Patients are followed by in-office and at-home </span></span>spirometry to assess the </span>peak inspiratory flow<span><span> (PIF), peak expiratory flow (PEF) and the PEF% values, along with quality-of-life instruments such as the RAND36, EQ5D and the new subglottic stenosis-specific, iSGS6. The initial procedure can be performed in the operating room using balloons and cold instruments to remove the subglottic scarring with injection of </span>triamcinolone acetate 40 mg/cc into the subglottis. Subsequent injections are performed in the awake-office setting at 3-week intervals until reaching a total of 6 injections (1 at surgery + 5 in-office). This single-surgeon experience with SILSI at Mass Eye and Ear now spans 13+ years, 95 patients and over 1,000 injections. A total of 58% (55/95) of patients have only required one SILSI Round (4 to 6 injections) while we have an overall success rate of 96% (91/95). A total of 95% of subjects (90/95) tolerated awake SILSI. The 52 patients with greater than 2 years of follow-up have an average follow-up of 68 months. As a group they started at a PEF% of 55% and ended their SILSI at a PEF% of 93%. Their most recent PEF% is 92% reflecting the lasting efficacy SILSI offers. As a group they underwent an average of 7 steroid injections and 1.6 surgeries resulting in an average of 36 months between interventions. A total of 29% of patients (15/52) in the Long-Term group have not had recurrences in the 53 months they have been followed. They have a group PEF% of 94% highlighting the durable SILSI effects allowing them to breath without restriction. SILSI is a safe and reliable method to treat airway stenosis that is rooted in many years of clinical success. These patients have excellent </span></span>quality of life<span> and can maintain a high level of breathing for much longer than those treated with balloon dilation (36 months vs. 12 months).</span></p></div>\",\"PeriodicalId\":39814,\"journal\":{\"name\":\"Operative Techniques in Otolaryngology - Head and Neck Surgery\",\"volume\":\"34 2\",\"pages\":\"Pages 120-128\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-06-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Operative Techniques in Otolaryngology - Head and Neck Surgery\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1043181023000313\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Operative Techniques in Otolaryngology - Head and Neck Surgery","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1043181023000313","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 1
摘要
连续病灶内类固醇注射(SILSI)作为特发性声门下狭窄的一线治疗方法在患者和医生中越来越受欢迎。患者随后接受办公室和家庭肺活量测定,以评估吸气峰值流量(PIF)、呼气峰值流量(PEF)和PEF%值,以及生活质量仪器,如RAND36、EQ5D和新的声门下狭窄特异性iSGS6。初始手术可在手术室进行,使用球囊和冷器械,在声门下注射醋酸曲安奈德40 mg/cc,去除声门下瘢痕。随后在清醒-办公室环境中每隔3周进行一次注射,直到总共注射6次(手术时1次+办公室内5次)。这个在Mass Eye and Ear的单一外科医生的SILSI经验现在已经超过13年,95名患者和1000多次注射。总共58%(55/95)的患者只需要一次SILSI Round(4至6次注射),而我们的总体成功率为96%(91/95)。共有95%的受试者(90/95)耐受清醒时的SILSI。随访2年以上的52例患者平均随访68个月。作为一个整体,他们以55%的PEF开始,以93%的PEF结束他们的SILSI。他们最近的PEF%为92%,反映了SILSI提供的持久功效。作为一个群体,他们平均接受了7次类固醇注射和1.6次手术,平均间隔36个月。长期组共有29%的患者(15/52)在随访的53个月里没有复发。他们有94%的组PEF%,突出了持久的SILSI效果,使他们可以不受限制地呼吸。SILSI是一种安全可靠的治疗气道狭窄的方法,根植于多年的临床成功。这些患者有很好的生活质量,可以保持高水平的呼吸比那些接受球囊扩张治疗的更长(36个月对12个月)。
Office based steroid injections for subglottic stenosis
Serial Intralesional Steroid Injection (SILSI) has been gaining popularity among patients and physicians as a first-line treatment for idiopathic subglottic stenosis. Patients are followed by in-office and at-home spirometry to assess the peak inspiratory flow (PIF), peak expiratory flow (PEF) and the PEF% values, along with quality-of-life instruments such as the RAND36, EQ5D and the new subglottic stenosis-specific, iSGS6. The initial procedure can be performed in the operating room using balloons and cold instruments to remove the subglottic scarring with injection of triamcinolone acetate 40 mg/cc into the subglottis. Subsequent injections are performed in the awake-office setting at 3-week intervals until reaching a total of 6 injections (1 at surgery + 5 in-office). This single-surgeon experience with SILSI at Mass Eye and Ear now spans 13+ years, 95 patients and over 1,000 injections. A total of 58% (55/95) of patients have only required one SILSI Round (4 to 6 injections) while we have an overall success rate of 96% (91/95). A total of 95% of subjects (90/95) tolerated awake SILSI. The 52 patients with greater than 2 years of follow-up have an average follow-up of 68 months. As a group they started at a PEF% of 55% and ended their SILSI at a PEF% of 93%. Their most recent PEF% is 92% reflecting the lasting efficacy SILSI offers. As a group they underwent an average of 7 steroid injections and 1.6 surgeries resulting in an average of 36 months between interventions. A total of 29% of patients (15/52) in the Long-Term group have not had recurrences in the 53 months they have been followed. They have a group PEF% of 94% highlighting the durable SILSI effects allowing them to breath without restriction. SILSI is a safe and reliable method to treat airway stenosis that is rooted in many years of clinical success. These patients have excellent quality of life and can maintain a high level of breathing for much longer than those treated with balloon dilation (36 months vs. 12 months).
期刊介绍:
This large-size, atlas-format journal presents detailed illustrations of new surgical procedures and techniques in otology, rhinology, laryngology, reconstructive head and neck surgery, and facial plastic surgery. Feature articles in each issue are related to a central theme by anatomic area or disease process. The journal will also often contain articles on complications, diagnosis, treatment or rehabilitation. New techniques that are non-operative are also featured.